Intrathecal Baclofen for Management of Spastic Cerebral Palsy: Multicenter Trial
- 1 February 2000
- journal article
- other
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 15 (2), 71-77
- https://doi.org/10.1177/088307380001500201
Abstract
Intrathecal baclofen infusion has demonstrated effectiveness in decreasing spasticity of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in cerebral palsy. This study assessed the effectiveness of intrathecal baclofen in reducing spasticity in cerebral palsy. Candidates were screened by randomized, double-blind, intrathecal injections of baclofen and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for spasticity. Responders received intrathecal baclofen via the SynchroMed System and were followed for up to 43 months. Fifty-one patients completed screening and 44 entered open-label trials. Lower-extremity spasticity decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper-extremity spasticity was evidenced over the same study period. Forty-two patients reported adverse events. Most common reports were hypotonia, seizures (no new onset), somnolence, and nausea or vomiting. Fifty-nine percent of the patients experienced procedural or system-related events. Spasticity in patients with cerebral palsy can be treated effectively by continuous intrathecal baclofen. Adverse events, although common, were manageable. (J Child Neurol 2000;15:71-77).Keywords
This publication has 9 references indexed in Scilit:
- Continuous Intrathecal Baclofen Infusion for Spasticity of Cerebral OriginJAMA, 1993
- Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter studyJournal of Neurosurgery, 1993
- Surgical Management of Spastic Diplegia in Cerebral PalsyNew England Journal of Medicine, 1992
- Intrathecal Baclofen for Spasticity in Cerebral PalsyJAMA, 1991
- Intrathecal Baclofen for Severe Spinal SpasticityNew England Journal of Medicine, 1989
- Pharmacokinetics of Intrathecal BaclofenPublished by Springer Nature ,1988
- Selenium: A Case for Its Essentiality in ManNew England Journal of Medicine, 1981
- Plasma and cerebrospinal fluid levels of baclofen (lioresal®) at optimal therapeutic responses in spastic paresisJournal of the Neurological Sciences, 1974
- BACLOFEN (LIORESAL) IN THE LONG‐TERM MANAGEMENT OF SPASTICITYThe Medical Journal of Australia, 1962